News

NFI Reports Impressive Q3 Growth Despite Challenges

NFI Reports Impressive Q3 Growth Despite Challenges

NFI Reports Significant Growth in Third Quarter

Improvements in Deliveries, Revenue, Free Cash Flow, Adjusted EBITDA, and Liquidity with a total backlog of $13.2 billion

(TSX: NFI, OTC: NFYEF) NFI Group Inc. has made waves in the transportation industry by announcing its interim financial results for third quarter 2025. The company, which is a key player in providing innovative mobility solutions, has showcased a remarkable performance amidst some operational hurdles.

Key Financial Highlights

Third Quarter Highlights

  • Deliveries: 1,114 equivalent units ("EUs"), with over a quarter being battery- and fuel cell-electric buses (“ZEBs”).
  • Revenue: $879.9 million, reflecting a year-over-year increase of 23.7%.
  • Gross Loss: $114.3 million; without the influence from battery recall warranty provisions, gross profit would have been reported at $115.6 million.
  • Net Loss: $140.9 million, translating to a Net Loss per Share of $1.18, primarily due to the battery recall provisions.
  • Adjusted Net Earnings: Reached $12.1 million, with Adjusted Net Earnings per Share of $0.10.
  • Net Cash from Operating Activities: $83.9 million, positively impacted by working capital benefits from advance customer payments and decreased interest and finance costs.
  • Adjusted EBITDA: $80.9 million, demonstrating a substantial year-over-year increase of 52.1%.
  • Backlog: An impressive $13.2 billion, showcasing a firm commitment with 5,774 EUs and additional 9,832 EUs as options, where ZEBs constitute 35.1% of the total backlog.
  • Return on Invested Capital (ROIC): Increased to 9.1%, up from 5.3% a year earlier.
  • Liquidity: Now stands at $386.0 million, a significant jump of 169.0% compared to the previous year.

Operational Insights from Leadership

CEO Paul Soubry expressed optimism regarding the company's trajectory, stating that the operational improvements have transitioned into enhanced revenue and margins per unit. The growth in Adjusted EBITDA and Free Cash Flow emphasizes NFI's commitment to enhancing liquidity while managing the impacts of a battery recall and associated warranty charges.

Soubry elaborated on the company's dedicated efforts towards performance enhancements, particularly focusing on their supply chain optimization strategies, including a joint venture to stabilize asset supply for American Seating.

Furthermore, NFI has been proactive in addressing aftermarket performance even amid fluctuating margins due to retrofit program contributions. Management is optimistic that strategic initiatives will foster improved prospects moving forward.

Navigating the Battery Recall Situation

The quarter also witnessed NFI's initiation of a voluntary battery recall affecting approximately 700 battery-electric buses due to risks associated with certain battery modules. Alongside operational guidelines put in place, the organization is working toward resolving the situation effectively, with a full battery replacement expected within 18 to 24 months starting in 2026.

Despite the financial burden of a $229.9 million warranty provision related to the recall, NFI remains committed to ensuring customer satisfaction and aligning operational capabilities with their operational mandates.

Market Outlook and Future Guidance

Looking forward, NFI's management is confident about future growth prospects driven by strong order activity. With the ongoing increase in public transit ridership and demand for electric vehicles, the company anticipates substantial customer orders in the coming quarters, underlined by an optimistic five-year forecast for U.S. demand for public transportation solutions.

NFI’s focus on zero-emission and sustainable transportation solutions positions the company well in the evolving mobility landscape.

Frequently Asked Questions

What financial metrics showed significant improvement for NFI in Q3?

NFI reported improvements in deliveries, revenue growth of 23.7%, Adjusted EBITDA growth of 52.1%, and increased liquidity of 169%.

How did the battery recall impact NFI's financial results?

The battery recall led to a net loss of $140.9 million and a warranty provision of $229.9 million, influencing gross margins and net earnings significantly.

What are NFI's future growth projections?

Given their strong backlog and market demand, NFI is optimistic about recording its highest quarterly Adjusted EBITDA performance to date in the next financial period.

What measures is NFI taking to address supply chain issues?

NFI is enhancing supply chain performance through joint ventures and strategic investments aimed at stabilizing operations and ensuring consistent supply for their customers.

What industry trends are influencing NFI's strategy?

The shift towards electrification in transportation and rising demand for public transit options are driving NFI's strategic initiatives focusing on sustainable mobility solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading

Top 5 Most Recently Viewed Articles

CAPREIT Welcomes Francine Moore to Board of Trustees

Updated Category News Views 162

CAPREIT Welcomes Francine Moore to Board of Trustees CAPREIT is excited to share that Ms. Francine Moore has been appointed as a new member of its Board of Trustees. This appointment took effect on November 7. Francine is known for her significant experience in the real estate sector, where she has built a remarkable career. Ms. Moore's Impressive Background With over 25...

Continue Reading
Cimpress Sees Target Adjustments Yet Remains Strong – A Deeper Look

Updated Category News Views 95

Cimpress Stock Target Adjustments and Outlook Recently, Truist Securities made notable adjustments to the stock price target for Cimpress N.V. (NASDAQ: CMPR), a recognized leader in mass customization solutions. The new target is now set at $110.00, reduced from the previous $120.00. Despite this adjustment, the firm has reiterated a Buy rating, showcasing confidence in...

Continue Reading
Significant Shift in NICUs: Embracing Prolacta's Innovations

Updated Category News Views 131

Transforming Neonatal Care with Prolacta's Nutritional Innovations Prolacta Offers the Only Nutritional Products Free From Cow Milk and Added Synthetic Ingredients for Extremely Premature Infants in the U.S. In an exciting development for neonatal care, Prolacta Bioscience® has reported that in 2025, the majority of Level III and IV neonatal intensive care units (NICUs)...

Continue Reading
Orchestry Unveils Automated Workspace Solutions for Microsoft 365

Updated Category News Views 127

Orchestry Launches Innovative Workspace Review for Teams and SharePoint Orchestry has introduced a groundbreaking feature that aims to transform the way IT administrators manage collaboration workspaces within Microsoft 365. This new capability, known as Workspace Review, not only automates the maintenance of these workspaces but also enhances security and compliance...

Continue Reading
The Investment Journey of Webster Financial Over Five Years

Updated Category News Views 151

Understanding Webster Financial's Growth Over the Years Webster Financial (NYSE: WBS) has demonstrated remarkable performance in the stock market, consistently outperforming many competitors. Over the past five years, it has achieved an impressive average annual return of 15.04%, surpassing the market by 1.25% annually. This impressive growth reflects the ongoing...

Continue Reading